Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Challenges to developing the quality of complex cancer surgery in LMICs

Share :

Choosing Wisely 2022 Mumbai

17 - 18 Sep 2022
Published: 19 Sep 2022
Views: 4916
Rating:
Save
Dr Shailesh V. Shrikhande - Tata Memorial Hospital, Mumbai, India

Dr Shrikhande speaks to ecancer about the challenges to developing the quality of complex cancer surgery in LMICs. 

He talks about maintaining the quality of life of cancer patients when treating them and how this can be a challenge. 

He also talks about the current situation of palliative care in India.

Related Videos

OncoAlert Round Up for September 15-21, 2023
Dr Gil Morgan - Executive Director, OncoAlert
OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )
25 Sep 2023
Time toxicity: the burden on cancer patients
Dr Arjun Gupta - University of Minnesota, Minneapolis, USA
Time toxicity: the burden on cancer patients ( Dr Arjun Gupta - University of Minnesota, Minneapolis, USA )
24 May 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...
Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )
2 May 2023
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small...
Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )
2 May 2023
The use of IORT at Universitätsmedizin Mannheim hospital
Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany
The use of IORT at Universitätsmedizin Mannheim hospital ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )
2 May 2023
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity...
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
26 Apr 2023
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in...
Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours ( Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA )
26 Apr 2023
VT3989 is safe and well tolerated in patients with advanced malignant...
Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA
VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )
25 Apr 2023
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...
Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )
25 Apr 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

An Error Occurred: Internal Server Error

Oops! An Error Occurred

The server returned a "500 Internal Server Error".

Something is broken. Please let us know what you were doing when this error occurred. We will fix it as soon as possible. Sorry for any inconvenience caused.